2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Schizophrenia

Schizophrenia

Schizophrenia is a severe and chronic mental disorder characterized by persistent or recurrent episodes of psychosis, including hallucinations, delusions, disorganized thinking and behavior, and negative symptoms such as social withdrawal and flattened affect. It typically emerges in early adulthood and is associated with significant impairment in daily functioning, cognitive deficits, and reduced quality of life. The disorder has a lifetime prevalence of approximately 1%, is highly heritable but genetically complex, and involves disruptions in brain function affecting perception, thought, and emotion regulation. While distinct from mood disorders and dementias, schizophrenia can co-occur with mood symptoms, leading to a schizoaffective disorder diagnosis in some cases. Core symptoms must persist for at least one month for diagnosis, with continuous or relapsing course lasting at least six months. Treatment includes antipsychotic medication, psychotherapy, family education, rehabilitation, and skills training. Genetic factors, such as variants in the MTHFR gene, and neurobiological pathways involving neurotransmitter systems and brain regions like the prefrontal cortex are implicated. Additional features may include sleep disturbances, photophobia, personality changes, EEG abnormalities, and movement problems.

Schizophrenia (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106820
    BRL 34778 86580-77-0
    BRL 34778 is a potent, selective and orally active dopamine D2 receptor antagonist with a Ki of 2.14 nM. BRL 34778 exhibits antipsychotic activity with low activity for extrapyramidal effects and sedation. BRL 34778 can be used for the research of neurological disease, such as schizophrenia.
    BRL 34778
  • HY-117021
    RO 5073012 1020814-70-3
    RO 5073012 is a selective, orally active and brain-penetrant TAAR1 agonist. RO 5073012 shows a Ki of 6 nM for hTAAR1 and EC50 values of 23 and 25 nM for mTAAR1 and rTAAR1. RO 5073012 can be used for the research of neurological disease, such as schizophrenia.
    RO 5073012
  • HY-19186
    PD-143188 150013-70-0
    PD-143188 (CI 1007) is a selective agonist targeting dopamine (DA) receptors, with Ki values of 25.5 nM and 16.6 nM for human D2 and D3 receptors, respectively and lower affinity for D4.2 receptors (Ki=90.9 nM). PD-143188 inhibits DA release, synthesis and metabolism, while reducing cellular cyclic AMP levels, exerting antipsychotic activity. PD-143188 is promising for research of psychopharmacology.
    PD-143188
  • HY-177873
    AMPA receptor modulator-10 620940-01-4
    AMPA receptor modulator-10 (Compound 9a) is an orally active AMPA receptor positive allosteric modulator. AMPA receptor modulator-10 exhibits potent activity (pEC50 = 5.0) on the GluA2 subtype of AMPAR, significantly enhancing glutamate-induced calcium influx and current responses. AMPA receptor modulator-10 can reverse the memory impairment induced by Scopolamine (HY-N0296) and enhance cognitive function. AMPA receptor modulator-10 can be used for the research of neurological disease, such as schizophrenia.
    AMPA receptor modulator-10